123 related articles for article (PubMed ID: 27941122)
1. First PET Imaging Studies With 63Zn-Zinc Citrate in Healthy Human Participants and Patients With Alzheimer Disease.
DeGrado TR; Kemp BJ; Pandey MK; Jiang H; Gunderson TM; Linscheid LR; Woodwick AR; McConnell DM; Fletcher JG; Johnson GB; Petersen RC; Knopman DS; Lowe VJ
Mol Imaging; 2016; 15():. PubMed ID: 27941122
[TBL] [Abstract][Full Text] [Related]
2. Preparation and preliminary evaluation of 63Zn-zinc citrate as a novel PET imaging biomarker for zinc.
DeGrado TR; Pandey MK; Byrne JF; Engelbrecht HP; Jiang H; Packard AB; Thomas KA; Jacobson MS; Curran GL; Lowe VJ
J Nucl Med; 2014 Aug; 55(8):1348-54. PubMed ID: 25047329
[TBL] [Abstract][Full Text] [Related]
3. Voxel-based analysis of Alzheimer's disease PET imaging using a triplet of radiotracers: PIB, FDDNP, and FDG.
Shin J; Lee SY; Kim SJ; Kim SH; Cho SJ; Kim YB
Neuroimage; 2010 Aug; 52(2):488-96. PubMed ID: 20385246
[TBL] [Abstract][Full Text] [Related]
4. Regional expansion of hypometabolism in Alzheimer's disease follows amyloid deposition with temporal delay.
Förster S; Grimmer T; Miederer I; Henriksen G; Yousefi BH; Graner P; Wester HJ; Förstl H; Kurz A; Dickerson BC; Bartenstein P; Drzezga A
Biol Psychiatry; 2012 May; 71(9):792-7. PubMed ID: 21679929
[TBL] [Abstract][Full Text] [Related]
5. Prefrontal hypometabolism in Alzheimer disease is related to longitudinal amyloid accumulation in remote brain regions.
Klupp E; Grimmer T; Tahmasian M; Sorg C; Yakushev I; Yousefi BH; Drzezga A; Förster S
J Nucl Med; 2015 Mar; 56(3):399-404. PubMed ID: 25678488
[TBL] [Abstract][Full Text] [Related]
6. In Alzheimer's disease, hypometabolism in low-amyloid brain regions may be a functional consequence of pathologies in connected brain regions.
Klupp E; Förster S; Grimmer T; Tahmasian M; Yakushev I; Sorg C; Yousefi BH; Drzezga A
Brain Connect; 2014 Jun; 4(5):371-83. PubMed ID: 24870443
[TBL] [Abstract][Full Text] [Related]
7. Biological characters of [18F]O-FEt-PIB in a rat model of Alzheimer's disease using micro-PET imaging.
Zheng MQ; Yin DZ; Zhang L; Lei B; Cheng DF; Cai HC; Han YJ; Wu MX; Zhang H; Wang J
Acta Pharmacol Sin; 2008 May; 29(5):548-54. PubMed ID: 18430362
[TBL] [Abstract][Full Text] [Related]
8. Characterization of 3 Novel Tau Radiopharmaceuticals,
Wong DF; Comley RA; Kuwabara H; Rosenberg PB; Resnick SM; Ostrowitzki S; Vozzi C; Boess F; Oh E; Lyketsos CG; Honer M; Gobbi L; Klein G; George N; Gapasin L; Kitzmiller K; Roberts J; Sevigny J; Nandi A; Brasic J; Mishra C; Thambisetty M; Mogekar A; Mathur A; Albert M; Dannals RF; Borroni E
J Nucl Med; 2018 Dec; 59(12):1869-1876. PubMed ID: 29728519
[No Abstract] [Full Text] [Related]
9. Characterization and first human investigation of FIBT, a novel fluorinated Aβ plaque neuroimaging PET radioligand.
Yousefi BH; Manook A; Grimmer T; Arzberger T; von Reutern B; Henriksen G; Drzezga A; Förster S; Schwaiger M; Wester HJ
ACS Chem Neurosci; 2015 Mar; 6(3):428-37. PubMed ID: 25482310
[TBL] [Abstract][Full Text] [Related]
10. Amyloid burden and metabolic function in early-onset Alzheimer's disease: parietal lobe involvement.
Ossenkoppele R; Zwan MD; Tolboom N; van Assema DM; Adriaanse SF; Kloet RW; Boellaard R; Windhorst AD; Barkhof F; Lammertsma AA; Scheltens P; van der Flier WM; van Berckel BN
Brain; 2012 Jul; 135(Pt 7):2115-25. PubMed ID: 22556189
[TBL] [Abstract][Full Text] [Related]
11. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.
Engler H; Forsberg A; Almkvist O; Blomquist G; Larsson E; Savitcheva I; Wall A; Ringheim A; Långström B; Nordberg A
Brain; 2006 Nov; 129(Pt 11):2856-66. PubMed ID: 16854944
[TBL] [Abstract][Full Text] [Related]
12. 18F-FDG PET Improves Diagnosis in Patients with Focal-Onset Dementias.
Taswell C; Villemagne VL; Yates P; Shimada H; Leyton CE; Ballard KJ; Piguet O; Burrell JR; Hodges JR; Rowe CC
J Nucl Med; 2015 Oct; 56(10):1547-53. PubMed ID: 26251415
[TBL] [Abstract][Full Text] [Related]
13. Dual-biomarker imaging of regional cerebral amyloid load and neuronal activity in dementia with PET and 11C-labeled Pittsburgh compound B.
Meyer PT; Hellwig S; Amtage F; Rottenburger C; Sahm U; Reuland P; Weber WA; Hüll M
J Nucl Med; 2011 Mar; 52(3):393-400. PubMed ID: 21321269
[TBL] [Abstract][Full Text] [Related]
14. Imaging zinc trafficking in vivo by positron emission tomography with zinc-62.
Firth G; Yu Z; Bartnicka JJ; Parker D; Kim J; Sunassee K; Greenwood HE; Al-Salamee F; Jauregui-Osoro M; Di Pietro A; Guzman J; Blower PJ
Metallomics; 2022 Oct; 14(10):. PubMed ID: 36201445
[TBL] [Abstract][Full Text] [Related]
15. [Molecular neuroimaging in the study of cognitive impairment: contribution of the cerebral blood flow SPECT with 99mTc-HMPAO and 18F-FDG PET/CT scan].
Banzo I; Quirce R; Martínez-Rodríguez I; Jiménez-Bonilla J; Portilla-Quattrociocchi H; Medina-Quiroz P; Ortega F; Rodríguez E; Mateo I; Vázquez-Higuera JL; de Arcocha M; Carril JM
Rev Esp Med Nucl; 2011; 30(5):301-6. PubMed ID: 21640440
[TBL] [Abstract][Full Text] [Related]
16. Impact of molecular imaging on the diagnostic process in a memory clinic.
Ossenkoppele R; Prins ND; Pijnenburg YA; Lemstra AW; van der Flier WM; Adriaanse SF; Windhorst AD; Handels RL; Wolfs CA; Aalten P; Verhey FR; Verbeek MM; van Buchem MA; Hoekstra OS; Lammertsma AA; Scheltens P; van Berckel BN
Alzheimers Dement; 2013 Jul; 9(4):414-21. PubMed ID: 23164552
[TBL] [Abstract][Full Text] [Related]
17. Florbetapir f-18: a histopathologically validated Beta-amyloid positron emission tomography imaging agent.
Lister-James J; Pontecorvo MJ; Clark C; Joshi AD; Mintun MA; Zhang W; Lim N; Zhuang Z; Golding G; Choi SR; Benedum TE; Kennedy P; Hefti F; Carpenter AP; Kung HF; Skovronsky DM
Semin Nucl Med; 2011 Jul; 41(4):300-4. PubMed ID: 21624563
[TBL] [Abstract][Full Text] [Related]
18. Whole-body biodistribution and brain PET imaging with [18F]AV-45, a novel amyloid imaging agent--a pilot study.
Lin KJ; Hsu WC; Hsiao IT; Wey SP; Jin LW; Skovronsky D; Wai YY; Chang HP; Lo CW; Yao CH; Yen TC; Kung MP
Nucl Med Biol; 2010 May; 37(4):497-508. PubMed ID: 20447562
[TBL] [Abstract][Full Text] [Related]
19. Amyloid PET in European and North American cohorts; and exploring age as a limit to clinical use of amyloid imaging.
Chiotis K; Carter SF; Farid K; Savitcheva I; Nordberg A;
Eur J Nucl Med Mol Imaging; 2015 Sep; 42(10):1492-506. PubMed ID: 26130168
[TBL] [Abstract][Full Text] [Related]
20. Construction and comparative evaluation of different activity detection methods in brain FDG-PET.
Buchholz HG; Wenzel F; Gartenschläger M; Thiele F; Young S; Reuss S; Schreckenberger M
Biomed Eng Online; 2015 Aug; 14():79. PubMed ID: 26281849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
